189 related articles for article (PubMed ID: 16037308)
1. Pyridoxamine: the many virtues of a maillard reaction inhibitor.
Voziyan PA; Hudson BG
Ann N Y Acad Sci; 2005 Jun; 1043():807-16. PubMed ID: 16037308
[TBL] [Abstract][Full Text] [Related]
2. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
Voziyan PA; Hudson BG
Cell Mol Life Sci; 2005 Aug; 62(15):1671-81. PubMed ID: 15905958
[TBL] [Abstract][Full Text] [Related]
3. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine.
Chetyrkin SV; Mathis ME; Ham AJ; Hachey DL; Hudson BG; Voziyan PA
Free Radic Biol Med; 2008 Apr; 44(7):1276-85. PubMed ID: 18374270
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
Chetyrkin SV; Zhang W; Hudson BG; Serianni AS; Voziyan PA
Biochemistry; 2008 Jan; 47(3):997-1006. PubMed ID: 18161948
[TBL] [Abstract][Full Text] [Related]
5. Vitamin B6 (pyridoxamine) supplementation and complications of diabetes.
Jain SK
Metabolism; 2007 Feb; 56(2):168-71. PubMed ID: 17224328
[No Abstract] [Full Text] [Related]
6. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Khalifah RG; Chen Y; Wassenberg JJ
Ann N Y Acad Sci; 2005 Jun; 1043():793-806. PubMed ID: 16037307
[TBL] [Abstract][Full Text] [Related]
7. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect.
Adrover M; Vilanova B; Frau J; Muñoz F; Donoso J
Bioorg Med Chem; 2008 May; 16(10):5557-69. PubMed ID: 18434162
[TBL] [Abstract][Full Text] [Related]
8. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.
Khalifah RG; Baynes JW; Hudson BG
Biochem Biophys Res Commun; 1999 Apr; 257(2):251-8. PubMed ID: 10198198
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
Peyroux J; Sternberg M
Pathol Biol (Paris); 2006 Sep; 54(7):405-19. PubMed ID: 16978799
[TBL] [Abstract][Full Text] [Related]
10. Effect of pyridoxamine on acrylamide formation in a glucose/asparagine model system.
Arribas-Lorenzo G; Morales FJ
J Agric Food Chem; 2009 Feb; 57(3):901-9. PubMed ID: 19143489
[TBL] [Abstract][Full Text] [Related]
11. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.
Kang Z; Li H; Li G; Yin D
Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947
[TBL] [Abstract][Full Text] [Related]
12. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
Reddy VP; Beyaz A
Drug Discov Today; 2006 Jul; 11(13-14):646-54. PubMed ID: 16793534
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products.
Culbertson SM; Enright GD; Ingold KU
Org Lett; 2003 Jul; 5(15):2659-62. PubMed ID: 12868883
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats.
Waanders F; van den Berg E; Nagai R; van Veen I; Navis G; van Goor H
Nephrol Dial Transplant; 2008 Feb; 23(2):518-24. PubMed ID: 17905804
[TBL] [Abstract][Full Text] [Related]
16. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Waanders F; van Goor H; Navis G
Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
[TBL] [Abstract][Full Text] [Related]
17. Pyridoxamine (BioStratum).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Apr; 6(4):410-8. PubMed ID: 15898348
[TBL] [Abstract][Full Text] [Related]
18. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions.
Voziyan PA; Khalifah RG; Thibaudeau C; Yildiz A; Jacob J; Serianni AS; Hudson BG
J Biol Chem; 2003 Nov; 278(47):46616-24. PubMed ID: 12975371
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the chemical reactivity of pyridoxamine, Ac-Phe-Lys and Ac-Cys with various glycating carbonyl compounds.
Adrover M; Vilanova B; Frau J; Muñoz F; Donoso J
Amino Acids; 2009 Mar; 36(3):437-48. PubMed ID: 18480960
[TBL] [Abstract][Full Text] [Related]
20. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts.
Peng X; Cheng KW; Ma J; Chen B; Ho CT; Lo C; Chen F; Wang M
J Agric Food Chem; 2008 Mar; 56(6):1907-11. PubMed ID: 18284204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
